13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
27 檔
27.8%
During the Q3 2025 filing period, Lion Point Capital, LP (CIK: 0001643354) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $20.9M across 27 reported positions.
Lion Point Capital, LP executed strategic sector rebalancing during Q3 2025, establishing 10 new positions while fully exiting 4 holdings and trimming 8 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 8.40% | -0.34% | -50.63% | |
| 2 | MIST | Milestone Pharmaceuticals In | Stock-Other | 7.48% | -0.57% | +20.00% | |
| 3 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 6.54% | +1.65% | -37.15% | |
| 4 | JSPR | Jasper Therapeutics Inc | Stock-Other | 5.39% | -1.50% | +172.05% | |
| 5 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 5.18% | — | -39.51% | |
| 6 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 5.16% | — | -49.02% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 5.11% | — | -41.31% | |
| 8 | ARDX | Ardelyx Inc | Stock-Other | 5.09% | -1.47% | -51.48% | |
| 9 | BNTC | Benitec Biopharma Inc | Stock-Other | 4.94% | +0.02% | — | |
| 10 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.81% | -1.27% | — | |
| 11 | RPRX | Royalty Pharma plc | Stock-Healthcare | 4.29% | -0.40% | — | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 3.98% | -0.27% | — | |
| 13 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.92% | -0.44% | -48.85% | |
| 14 | GERN | Geron CORP | Stock-Other | 3.89% | -1.61% | — | |
| 15 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 3.78% | -0.08% | -23.76% | |
| 16 | RGNX | Regenxbio Inc | Stock-Other | 3.17% | +0.19% | — | |
| 17 | MCRB | Seres Therapeutics Inc | Stock-Other | 2.97% | -0.48% | +59.28% | |
| 18 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.75% | -1.23% | — | |
| 19 | KURA | Kura Oncology Inc | Stock-Other | 2.31% | +0.17% | — | |
| 20 | BHVN | Biohaven Ltd. | Stock-Other | 1.94% | +1.07% | — | |
| 21 | CMPS | Compass Pathways PLC | Stock-Other | 1.89% | +2.77% | — | |
| 22 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.72% | -1.44% | — | |
| 23 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.68% | — | — | |
| 24 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.59% | -0.43% | — | |
| 25 | MRSN | Mersana Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 26 | HUMA | Humacyte Inc | Stock-Other | 0.83% | +0.07% | — | |
| 27 | SPRB | Spruce Biosciences Inc | Stock-Other | 0.05% | -0.13% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIST | Milestone Pharmaceuticals In | +4.7% | +20.00% | Add |
| 2 | JSPR | Jasper Therapeutics Inc | +1.4% | +172.05% | Add |
| 3 | IRON | Disc Medicine Inc | +0.6% | — | Unchanged |
| 4 | RGNX | Regenxbio Inc | +0.5% | — | Unchanged |
| 5 | SNDX | Syndax Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 6 | MLYS | Mineralys Therapeutics Inc | +0.4% | -50.63% | Trim |
| 7 | ✓ | Avadel Pharmaceuticals PLC ADR | +0.3% | -39.51% | Trim |
| 8 | HUMA | Humacyte Inc | -0.1% | — | Unchanged |
| 9 | BNTC | Benitec Biopharma Inc | -0.2% | — | Unchanged |
| 10 | ARQT | Arcutis Biotherapeutics Inc | -0.8% | -23.76% | Trim |
| 11 | FENC | Fennec Pharmaceuticals Inc | -1.1% | -37.15% | Trim |
| 12 | GERN | Geron CORP | -1.2% | — | Unchanged |
| 13 | KNSA | Kiniksa Pharmaceuticals International, plc | -1.3% | -49.02% | Trim |
| 14 | BHVN | Biohaven Ltd. | -1.5% | — | Unchanged |
| 15 | BBIO | Bridgebio Pharma Inc | -1.8% | -48.85% | Trim |
| 16 | ARDX | Ardelyx Inc | -5.4% | -51.48% | Trim |
| 17 | INSM | Insmed Inc | -9.7% | -41.31% | Trim |
| 18 | RPRX | Royalty Pharma plc | — | NEW | New buy |
| 19 | MCRB | Seres Therapeutics Inc | — | NEW | New buy |
| 20 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 21 | KURA | Kura Oncology Inc | — | NEW | New buy |
| 22 | BLE0 | Bluebird Bio Inc | — | EXIT | Sold out |
| 23 | CMPS | Compass Pathways PLC | — | NEW | New buy |
| 24 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 25 | DAWNGBX | Day One Biopharmaceuticals I | — | NEW | New buy |
| 26 | RCKT | Rocket Pharmaceuticals Inc | — | NEW | New buy |
| 27 | MCRB1EUR | Seres Therapeutics Inc | — | EXIT | Sold out |
| 28 | ✓ | Mersana Therapeutics Inc | — | EXIT | Sold out |
| 29 | MRSN | Mersana Therapeutics Inc | — | NEW | New buy |
| 30 | SPRU | Spruce Power Holding Corporation | — | EXIT | Sold out |
| 31 | SPRB | Spruce Biosciences Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 27 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MLYS, MIST, FENC) accounted for 27.8% of total reported equity market value during Q3 2025.
Top New Position Initiated
RPRX
市值: $755.0K
Top Position Liquidated / Trimmed
BLE0
前期市值: $385.1K
During Q3 2025, Lion Point Capital, LP's top holdings by market value included MLYS (8.4%)、MIST (7.5%)、FENC (6.5%). The largest single position, MLYS, represented 8.4% of total portfolio value.
In Q3 2025, Lion Point Capital, LP made 24 total portfolio adjustments, initiating 10 new buys, adding to 2 positions, trimming 8 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.